ANDA 70290, held by Chartwell RX. Tolazamide.
As of Nov 21, 2026, ANDA 70290 (Tolazamide), held by Chartwell RX, was first approved by FDA on Mar 13, 1986, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tolazamide500MG · tablet;oral | Tolazamide | Discontinued |
| May 9, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Apr 3, 1996 | Supplement 11Manufacturing | Approved | None posted |
| Oct 24, 1995 | Supplement 10Manufacturing | Approved | None posted |
| Jul 24, 1992 | Supplement 8Labeling | Approved | None posted |
| Mar 14, 1990 | Supplement 7Manufacturing | Approved | None posted |
| May 9, 1989 | Supplement 6Labeling | Approved | None posted |
| Nov 8, 1988 | Supplement 5Manufacturing | Approved | None posted |
| Dec 23, 1987 | Supplement 1Manufacturing | Approved | None posted |
| Dec 23, 1987 | Supplement 2Manufacturing | Approved | None posted |
| Dec 23, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Mar 13, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters